Denosumab combined with immunotherapy, radiotherapy, and granulocyte-macrophage colony-stimulating factor for the treatment of metastatic nasopharyngeal carcinoma: A case report

Figure 1 Examinations. A: The Epstein–Barr virus DNA changes during PRaG treatment; B: Computed tomography (CT) evaluation of sternal metastases at baseline and during treatment; C: CT evaluation of right iliac metastases at baseline and during treatment; D: Bone scans of the patient at baseline and during treatment; E Initial pathology and immunohistochemistry of the patient hematoxylin and eosin stain, mutS homolog (MSH) 2, MSH6, PMS1 homolog 2, and mutL homolog 1; F: The interleukin-6 changes during PRaG treatment. EB: Epstein–Barr; IL: Interleukin; HE: Hematoxylin and eosin; MSH2: MutS homolog 2; MSH6: MutS homolog 6; PMS2: PMS1 homolog 2; MLH1: MutL homolog 1.